» Articles » PMID: 25797122

Regadenoson Versus Dipyridamole Hyperemia for Cardiac PET Imaging

Overview
Publisher Elsevier
Date 2015 Mar 24
PMID 25797122
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The goal of this study was to compare regadenoson and dipyridamole hyperemia for quantitative myocardial perfusion imaging.

Background: Regadenoson is commonly used for stress perfusion imaging. However, no study in nuclear cardiology has employed a paired design to compare quantitative hyperemic flow from regadenoson to more traditional agents such as dipyridamole. Additionally, the timing of regadenoson bolus relative to tracer administration can be expected to affect quantitative flow.

Methods: Subjects underwent 2 rest/stress cardiac positron emission tomography scans using an Rb-82 generator. Each scan employed dipyridamole and a second drug in random sequence, either regadenoson according to 5 timing sequences or repeated dipyridamole. A validated retention model quantified absolute flow and coronary flow reserve.

Results: A total of 176 pairs compared regadenoson (126 pairs, split unevenly among 5 timing sequences) or repeated dipyridamole (50 pairs). The cohort largely had few symptoms, only risk factors, and nearly normal relative uptake images, with 8% typical angina or dyspnea, 20% manifest coronary artery disease, and a minimum quadrant average of 80% (interquartile range: 76% to 83%) on dipyridamole scans. Hyperemic flow varied among regadenoson timing sequences but showed consistently lower stress flow and coronary flow reserve compared with dipyridamole. A timing sequence most similar to the regadenoson package insert achieved about 80% of dipyridamole hyperemia, whereas further delaying radiotracer injection reached approximately 90% of dipyridamole hyperemia. Because of the small numbers of pairs for each regadenoson timing protocol and a paucity of moderate or large perfusion defects, we did not observe a difference in relative uptake.

Conclusions: With the standard timing protocol from the package insert, regadenoson achieved only 80% of dipyridamole hyperemia quantitatively imaged by cardiac positron emission tomography using Rb-82. A nonstandard protocol using a more delayed radionuclide injection after the regadenoson bolus improved its effect to 90% of dipyridamole hyperemia.

Citing Articles

Feasibility of Simultaneous Quantification of Myocardial and Renal Perfusion With Cardiac Positron Emission Tomography.

Brown J, Park M, Kijewski M, Weber B, Yang Y, Martell L Circ Cardiovasc Imaging. 2023; 16(9):e015324.

PMID: 37655498 PMC: 10529360. DOI: 10.1161/CIRCIMAGING.123.015324.


A highly predictive cardiac positron emission tomography (PET) risk score for 90-day and one-year major adverse cardiac events and revascularization.

McCubrey R, Mason S, Le V, Bride D, Horne B, Meredith K J Nucl Cardiol. 2022; 30(1):46-58.

PMID: 36536088 PMC: 10035554. DOI: 10.1007/s12350-022-03028-y.


Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy Is Prognostic for Post-Transplant Events.

Clerkin K, Topkara V, Farr M, Jain R, Colombo P, Restaino S J Am Coll Cardiol. 2022; 80(17):1617-1628.

PMID: 36265957 PMC: 9758655. DOI: 10.1016/j.jacc.2022.08.751.


Safety and Efficacy of Regadenoson for Pediatric Stress Perfusion Cardiac MRI with Quantification of Myocardial Blood Flow.

Patel S, Husain N, Rigsby C, Robinson J Children (Basel). 2022; 9(9).

PMID: 36138640 PMC: 9497237. DOI: 10.3390/children9091332.


Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease.

Kero T, Saraste A, Lagerqvist B, Sorensen J, Pikkarainen E, Lubberink M J Nucl Cardiol. 2021; 29(1):24-36.

PMID: 34386859 PMC: 8873130. DOI: 10.1007/s12350-021-02731-6.